Tennessee Oncology is home to one of the leading clinical trial networks in the country. We offer a broad menu of trial opportunities in every phase of treatment. Use the search below to discover and learn more about our clinical trials:
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination with Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study
Condition: Multiple Solid Tumors
TO Study: MULTI 67
Clinic:
Cleveland, Chattanooga Downtown, Med Park 2, Memorial
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
Condition: Multiple Myeloma
TO Study: MM24014
Clinic:
Midtown, Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) (SUCCESSOR-2)
Condition: Multiple Myeloma
TO Study: MM24009
Clinic:
Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer, Centennial Medical Center, Midtown, Murfreesboro, Smyrna
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/​Refractory Mantle Cell Lymphoma
Condition: Mantle Cell Lymphoma
TO Study: LYM24022
Clinic:
Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer, Midtown, St. Thomas West, Centennial Medical Center
A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-601) Administered to Patients with Relapsed or Refractory Non-Hodgkin Lymphoma (NHL [APOLLO])
Condition: Chronic Lymphocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Large B-Cell Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
TO Study: LYM 211
Clinic:
Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Condition: Non-small Cell Lung Cancer
TO Study: LUN24026
Clinic:
Centennial Medical Center, Lebanon, Skyline, Smyrna, Dickson, Midtown, Southern Hills, Franklin, Murfreesboro, Mt. Juliet, Gallatin, St. Thomas West, Hendersonville, Shelbyville, Cleveland, Chattanooga Downtown, Dalton, Med Park 2, Memorial
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Condition: Multiple Solid Tumors, Non-small Cell Lung Cancer
TO Study: MULTI24006
Clinic:
Centennial Medical Center, Lebanon, Skyline, Smyrna, Dickson, Midtown, Southern Hills, Franklin, Murfreesboro, Mt. Juliet, Gallatin, St. Thomas West, Hendersonville, Shelbyville, Cleveland, Chattanooga Downtown, Dalton, Med Park 2, Memorial
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (SUNRAY-01)
Condition: Non-small Cell Lung Cancer
TO Study: LUN24032
Clinic:
Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Mt. Juliet, Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills, Cleveland, Chattanooga Downtown, Dalton, Med Park 2, Memorial
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (ELEGANT)
Condition: Breast Cancer: HR+/HER2-
TO Study: BRE24013
Clinic:
Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Mt. Juliet, Murfreesboro, St. Thomas West, Shelbyville, Skyline, Southern Hills, Smyrna
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator’s Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer (rechARge)
Condition: Prostate Cancer
TO Study: GU24007
Clinic:
Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Mt. Juliet, Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1)
Condition: Breast Cancer: HR+/HER2-
TO Study: BRE23008
Clinic:
Centennial Medical Center, Midtown, Murfreesboro, Mt. Juliet, Shelbyville, Smyrna, Chattanooga Downtown, Med Park 2, Memorial
Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC)
Condition: Breast Cancer: Triple Negative
TO Study: BRE 360
Clinic:
Cleveland, Chattanooga Downtown, Med Park 2, Memorial
(EXPANSION) A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally to Patients with Advanced or Metastatic Solid Tumors
Condition: Multiple Solid Tumors
TO Study: RM 721
Clinic:
Cleveland, Chattanooga Downtown, Med Park 2, Memorial
Phase 2 Open-label Study to Evaluate Momelotinib in Combination with Luspatercept in Participants with Transfusion Dependent Primary or Secondary Myelofibrosis
Condition: Myelofibrosis
TO Study: MPN24004
Clinic:
Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Midtown Center for Blood Cancer, Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills, Tennessee Oncology Center for Blood Cancer, Cleveland, Chattanooga Downtown, Med Park 2, Memorial
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
Condition: Myelofibrosis
TO Study: MPN24003
Clinic:
Cleveland, Chattanooga Downtown, Med Park 2, Memorial, Dalton, Ringgold, Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Midtown Center for Blood Cancer, Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills, Tennessee Oncology Center for Blood Cancer
MMRC HORIZON ONE: A PHASE II RANDOMIZED ADAPTIVE PLATFORM TRIAL EVALUATING NOVEL THERAPIES IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Condition: Multiple Myeloma
TO Study: MM24011
Clinic:
Midtown, Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer, Midtown, Centennial Medical Center, Murfreesboro, Smyrna, Chattanooga Downtown, Med Park 2, Memorial
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
TO Study: MM23002
Clinic:
Tennessee Oncology Center for Blood Cancer, Midtown Center for Blood Cancer
Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Treatment after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)
Condition: Multiple Myeloma
TO Study: MM 163
Clinic:
Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Midtown Center for Blood Cancer, Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills, Tennessee Oncology Center for Blood Cancer
Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (CAMMOUFLAGE Trial)
Condition: Multiple Myeloma
TO Study: MM 161
Clinic:
Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer
A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
TO Study: MM 159
Clinic:
Tennessee Oncology Center for Blood Cancer, Midtown Center for Blood Cancer
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
Condition: Multiple Myeloma
TO Study: MM 136
Clinic:
Lebanon, Murfreesboro, Shelbyville, Mt. Juliet, Midtown Center for Blood Cancer, Midtown, Centennial Medical Center, Gallatin, Tennessee Oncology Center for Blood Cancer
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Condition: Large B-Cell Lymphoma
TO Study: LYM24006
Clinic:
Centennial Medical Center, Midtown Center for Blood Cancer, Midtown, Tennessee Oncology Center for Blood Cancer, Chattanooga Downtown, Med Park 2, Memorial
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Treatment as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23)
Condition: Large B-Cell Lymphoma
TO Study: LYM 206
Clinic:
Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer
A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton’s Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies.
Condition: Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Primary Central Nervous System Lymphoma, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia
TO Study: LYM 184
Clinic:
Midtown Center for Blood Cancer, Tennessee Oncology Center for Blood Cancer
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
Condition: Follicular Lymphoma
TO Study: LYM 170
Clinic:
Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Midtown Center for Blood Cancer, Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills, Tennessee Oncology Center for Blood Cancer
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy…
Condition: Non-small Cell Lung Cancer
TO Study: LUN24030
Clinic:
Gallatin, Mt. Juliet, Murfreesboro, St. Thomas West, Lebanon, Chattanooga Downtown, Med Park 2, Memorial
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR – HN1)
Condition: Head and Neck Squamous Cell Carcinoma
TO Study: HN24004
Clinic:
Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Murfreesboro, St. Thomas West, Shelbyville, Skyline, Southern Hills, Mt. Juliet, Cleveland, Chattanooga Downtown, Dalton, Med Park 2, Memorial
A Phase 3 Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared with Investigator’s Choice Monotherapy Treatment in Previously Treated Patients with Incurable, Metastatic/recurrent Head and Neck Squamous Cell Carcinoma
Condition: Head and Neck Squamous Cell Carcinoma
TO Study: HN23003
Clinic:
Centennial Medical Center, Lebanon, Skyline, Smyrna, Dickson, Midtown, Southern Hills, Franklin, Murfreesboro, Mt. Juliet, Gallatin, St. Thomas West, Hendersonville, Shelbyville, Cleveland, Chattanooga Downtown, Dalton, Med Park 2, Memorial
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
TO Study: LUN23013
Clinic:
Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills
A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants with EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer whose Disease has Progressed on…
Condition: Non-small Cell Lung Cancer
TO Study: LUN24015
Clinic:
Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills, Mt. Juliet
A randomized, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) and secondary resistance to Immune Checkpoint Inhibitor (ICI)- ARTEMIA…
Condition: Non-small Cell Lung Cancer
TO Study: LUN24016
Clinic:
Centennial Medical Center, Lebanon, Skyline, Smyrna, Dickson, Midtown, Southern Hills, Franklin, Murfreesboro, Mt. Juliet, Gallatin, St. Thomas West, Hendersonville, Shelbyville, Cleveland, Chattanooga Downtown, Dalton, Med Park 2, Memorial
A Phase III, Randomized, Double-Blind, Multicenter, Global Study of Rilvegostomig in Combination with Chemotherapy for First-line Treatment of Patients with Metastatic Non-squamous Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (TC ≥ 1%) (ARTEMIDE-Lung03)
Condition: Non-small Cell Lung Cancer
TO Study: LUN24029
Clinic:
Centennial Medical Center, Lebanon, Skyline, Smyrna, Dickson, Midtown, Southern Hills, Franklin, Murfreesboro, Mt. Juliet, Gallatin, St. Thomas West, Hendersonville, Shelbyville, Cleveland, Chattanooga Downtown, Dalton, Med Park 2, Memorial
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE)
Condition: Head and Neck Squamous Cell Carcinoma
TO Study: HN23002
Clinic:
Centennial Medical Center, Lebanon, Skyline, Smyrna, Dickson, Midtown, Southern Hills, Franklin, Murfreesboro, Mt. Juliet, Gallatin, St. Thomas West, Hendersonville, Shelbyville, Cleveland, Chattanooga Downtown, Dalton, Med Park 2, Memorial, Ringgold
A Phase I/II Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma or Multiple Myeloma
Condition: Multiple Myeloma
TO Study: HR 68
Clinic:
Tennessee Oncology Center for Blood Cancer, Midtown Center for Blood Cancer
A Study of Amivantamab and FOLFIRI Versus Cetuximab/​Bevacizumab and FOLFIRI in Participants With KRAS/​NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy (OrigAMI-3)
Condition: Colorectal Cancer
TO Study: GI24012
Clinic:
Midtown, Murfreesboro, Smyrna, Chattanooga Downtown, Med Park 2, Memorial
First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of GIM-122 as a Single Agent in Adult Subjects with Advanced Solid Malignancies
Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination with Anti-PD-1 in Advanced Solid Tumors
Phase II, Open-Label, Prospective Single-Arm, Multi-Center Clinical Trial to Evaluate if Adding Venetoclax to Patients on Covalent BTKI for 1L CLL Can Achieve Deep Durable Remissions (BY uMRD 10^-4) to Allow Off-Treatment Period​
Condition: Chronic Lymphocytic Leukemia
TO Study: CLL24004
Clinic:
Centennial Medical Center, Lebanon, Skyline, Midtown Center for Blood Cancer, Smyrna, Dickson, Midtown, Southern Hills, Franklin, Murfreesboro, Mt. Juliet, Gallatin, St. Thomas West, Tennessee Oncology Center for Blood Cancer, Hendersonville, Shelbyville, Cleveland, Chattanooga Downtown, Dalton, Med Park 2, Memorial, Ringgold
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer…
Condition: Breast Cancer: HR+/HER2-
TO Study: BRE24011
Clinic:
Centennial Medical Center, Lebanon, Skyline, Smyrna, Dickson, Midtown, Southern Hills, Franklin, Murfreesboro, Mt. Juliet, Gallatin, St. Thomas West, Hendersonville, Shelbyville
Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan(Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment…
Condition: Breast Cancer: Triple Negative
TO Study: BRE23005
Clinic:
Cleveland, Chattanooga Downtown, Med Park 2, Memorial, Centennial Medical Center, Dickson, Franklin, Gallatin, Hendersonville, Lebanon, Midtown, Murfreesboro, St. Thomas West, Shelbyville, Skyline, Smyrna, Southern Hills, Mt. Juliet
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive…
Condition: Breast Cancer: Triple Negative
TO Study: BRE23006
Clinic:
Centennial Medical Center, Lebanon, Skyline, Smyrna, Dickson, Midtown, Southern Hills, Franklin, Murfreesboro, Mt. Juliet, Gallatin, St. Thomas West, Hendersonville, Shelbyville, Cleveland, Chattanooga Downtown, Dalton, Med Park 2, Memorial, Ringgold
